https://biotechmorning.com/news/electra-therapeutics-350m-ipo-sirp-antibody Biotech Morning en 2026-09-18T14:19:38.796Z The $350M Bet on a Protein Most People Have Never Heard Of https://biotechmorning.com/news/xenon-depression-drug-psychosis-pause Biotech Morning en 2026-09-18T14:18:48.614Z Xenon's Depression Drug Just Triggered the One Side Effect You Never Want to See https://biotechmorning.com/news/fayuvi-gene-therapy-sanfilippo-syndrome-approval Biotech Morning en 2026-09-18T14:18:04.725Z The $3.95 Million Shot That Could Save a Child's Brain https://biotechmorning.com/news/genentech-190m-hanmi-preclinical-obesity-deal Biotech Morning en 2026-09-18T14:17:18.806Z Genentech Just Paid $190M for a Drug That's Never Been in a Human https://biotechmorning.com/news/novo-nordisk-orbis-medicines-oral-macrocycle-deal Biotech Morning en 2026-09-18T14:16:30.813Z Novo Nordisk Just Paid $1.4B for a Chemistry Trick Most Pharma Gave Up On https://biotechmorning.com/news/enhertu-nhs-england-approval-breast-cancer Biotech Morning en 2026-09-18T14:15:39.760Z The Cancer Drug England Couldn't Afford Just Got a Second Chance https://biotechmorning.com/news/315m-preclinical-parkinsons-deal-sk-biopharmaceuticals Biotech Morning en 2026-09-18T14:14:57.234Z $315M for a Drug That Doesn't Exist Yet https://biotechmorning.com/news/novartis-als-trial-failure-lifonebart Biotech Morning en 2026-09-18T14:14:06.673Z ALS Just Broke Another Heart. This Time It Was Novartis. https://biotechmorning.com/news/bms-orum-dac-phase-1-termination Biotech Morning en 2026-09-18T14:13:18.205Z BMS Just Torched $100M on a Drug That Never Made It Past Phase 1 https://biotechmorning.com/news/trutakna-origin-3-kidney-disease-zero-progression Biotech Morning en 2026-09-18T14:12:34.668Z Zero Patients Progressed. This Kidney Drug's Numbers Are Almost Too Good. https://biotechmorning.com/news/kerendia-type-1-diabetes-ckd-approval Biotech Morning en 2026-09-17T14:17:19.125Z 30 Years Without a New Drug. Type 1 Diabetes Patients Just Got One. https://biotechmorning.com/news/pd1-agonist-rheumatoid-arthritis-jak-like-efficacy Biotech Morning en 2026-09-17T14:16:38.728Z A Cancer Drug's Evil Twin Might Be the Best Thing to Happen to Arthritis https://biotechmorning.com/news/novartis-sironax-brain-delivery-platform-deal Biotech Morning en 2026-09-17T14:15:55.266Z Novartis Just Paid $125M for a Key to the Brain's Front Door https://biotechmorning.com/news/pfizer-10-billion-metsera-obesity-acquisition Biotech Morning en 2026-09-17T14:15:02.691Z Pfizer Just Spent $10 Billion to Crash the Obesity Party https://biotechmorning.com/news/lilly-twist-bioscience-tunelab-ai-antibody-discovery Biotech Morning en 2026-09-17T14:14:16.972Z Lilly's Secret Weapon for Finding Better Antibodies Isn't a Lab https://biotechmorning.com/news/acelot-oral-tdp43-als-drug-first-dosing Biotech Morning en 2026-09-17T14:13:33.890Z The Pill Chasing ALS's Most Elusive Target https://biotechmorning.com/news/skyhawk-huntingtons-rna-splicing-therapy-15-month-data Biotech Morning en 2026-09-17T14:12:43.138Z The Huntington's Drug That's Doing What Others Couldn't https://biotechmorning.com/news/oral-pill-thyroid-eye-disease-sling-therapeutics Biotech Morning en 2026-09-17T14:12:00.482Z The Pill That Wants to Kill a $2 Billion Needle https://biotechmorning.com/news/roche-dualitas-bispecific-antibody-screening-deal Biotech Morning en 2026-09-17T14:11:16.044Z Roche Just Paid $36.5M for a Machine That Tests 300,000 Antibody Combos https://biotechmorning.com/news/novo-nordisk-anthropic-claude-ai-drug-development Biotech Morning en 2026-09-17T14:10:22.354Z Novo Nordisk Just Hired the Brainiest AI in the Room